S-1/A: Upexi Shifts to Solana Treasury, Reports Mixed Financials
Registration Statement Amendment
Upexi, Inc. is pivoting its strategy to focus on a Solana digital asset treasury and consumer products, despite significant revenue declines but improved gross profit margins.
Summary
- Upexi, Inc. has transitioned its core business strategy from a diverse consumer products portfolio to primarily a Solana (SOL) digital asset holding and staking company, alongside its branded consumer products.
- The company reported a substantial revenue decline of 45% to $11,522,487 for the nine months ended March 31, 2025, compared to $20,960,812 in the prior year, largely due to a strategic shift away from its recommerce business.
- Despite the revenue drop, the gross profit margin increased significantly to 64% for the nine months ended March 31, 2025, up from 54% in the same period last year, indicating improved profitability on remaining sales.
- Net loss from continuing operations decreased to $(6,758,547) for the nine months ended March 31, 2025, from $(7,912,919) in the prior year, a reduction of $1,153,805.
- Working capital deteriorated significantly, showing a deficit of $(6,828,044) as of March 31, 2025, compared to $(1,235,234) at June 30, 2024.
- Upexi raised $100 million in April 2025 and an additional $50 million in July 2025 through private placements, along with a $151.2 million convertible note offering, to fund its Solana treasury strategy.
- As of March 31, 2025, the company held 359 Solana Tokens with a carrying value of $44,732, but subsequently purchased approximately 596,355 Solana Tokens for about $84,157,000.
- Approximately 95% of the company's SOL treasury is currently staked to earn yield, with a target to maintain a similar or higher percentage.
- The company utilizes multiple qualified third-party custodians, including BitGo Trust Company, Inc. and Coinbase Inc., for its Solana holdings, with over 98% in cold storage.
- Upexi has divested several subsidiaries, including Infusionz, Interactive Offers, VitaMedica, and E-Core Technology, Inc., to streamline operations and focus on its new strategy.
Sentiment
Score: 4
Explanation: The company is undergoing a significant strategic pivot into a highly volatile and regulated asset class (Solana), while its traditional consumer products business experienced substantial revenue decline. Although net losses decreased and gross margins improved, the significant deterioration in working capital and the inherent risks of the crypto strategy warrant a cautious outlook. The large capital raises are positive for funding the new strategy but also highlight the capital intensity of the pivot.
Positives
- Gross profit margin increased by 10 percentage points to 64% for the nine months ended March 31, 2025, indicating better efficiency or product mix in continuing operations.
- Net loss from continuing operations decreased by $1,153,805 for the nine months ended March 31, 2025, compared to the prior year.
- Successfully raised significant capital: $100 million in April 2025 and $50 million in July 2025 through private placements, plus a $151.2 million convertible note offering.
- The company has a clear strategy to generate yield by staking approximately 95% of its Solana treasury.
- Utilizes multiple qualified third-party custodians (BitGo, Coinbase) and maintains over 98% of SOL treasury in cold storage to mitigate risk.
Negatives
- Revenue declined by 45% ($9,438,325) for the nine months ended March 31, 2025, primarily due to the strategic shift away from the recommerce business and a net decline in branded products and manufacturing.
- Working capital deficit significantly worsened to $(6,828,044) as of March 31, 2025, from $(1,235,234) at June 30, 2024.
- Cash balance decreased by $431,023 to $230,392 as of March 31, 2025, from June 30, 2024.
- Management reserved accounts receivables owed by Amazon, unable to reasonably estimate recovery, indicating potential collection issues.
- The company incurred significantly more legal and auditing costs during the nine months ended March 31, 2025, related to the change in strategy and business restructuring.
- Insurance policies from custodians (BitGo: $250M, Coinbase: $250K cash, <$6M SOL) are not adequate to fully cover the company's current SOL treasury value of approximately $253 million at BitGo.
- The company has a limited operating history with its current scale and new business focus on cryptocurrency, making future performance difficult to forecast.
Risks
- Upexi does not anticipate paying any dividends on its common stock in the foreseeable future, reinvesting profits back into the business.
- Future equity or debt offerings could lead to additional dilution for existing shareholders, and sales of a substantial number of shares could depress the market price.
- The company's limited operating history makes it difficult for potential investors to evaluate business prospects and management, with no assurance of future profitability.
- Inability to protect intellectual property rights could harm the company's competitive position and brand value.
- Failure to effectively manage growth could place substantial strain on managerial, operational, and financial resources.
- Quarterly financial results are expected to fluctuate significantly due to factors like product demand, customer retention, inventory management, economic conditions, and marketing costs.
- Compliance with U.S. federal securities laws and the Sarbanes-Oxley Act is expensive and time-consuming, potentially diverting management attention.
- Cybersecurity breaches of IT systems could degrade business operations, compromise data, result in losses, damage reputation, and incur significant costs.
- Increases in costs, disruption of supply, or shortage of raw materials (e.g., industrial hemp) could harm the business and reduce margins.
- Failure to meet Nasdaq Capital Market listing requirements could result in delisting, negatively affecting share price and liquidity.
- Operating in a highly competitive environment in both consumer products and digital asset staking, with many competitors having greater resources.
- Unfavorable publicity or consumer perception of products, especially hemp-based items, could materially adversely affect reputation and sales.
- Failure to attract and retain key employees could materially harm the business.
- Substantial risk of product liability claims and potential adverse product publicity, with limited clinical data on industrial hemp-based products.
- Inability to attract and retain independent distributors for products could negatively impact sales.
- Potential obligations resulting from the activities of independent distributors, including reclassification as employees or liability for false claims.
- The launch of central bank digital currencies (CBDCs) may adversely impact the demand for private-sector cryptocurrencies like Solana.
- There is a risk that Solana may be classified as a security by regulatory bodies, subjecting the company to additional regulation and potentially impacting business operations.
- If deemed an investment company under the 1940 Act, applicable restrictions would likely make it impractical to continue segments of the business as contemplated.
- Regulatory developments related to crypto assets and markets could adversely affect the price of Solana and the company's business.
- Reliance on an asset manager (GSR Strategies, LLC) for investment strategy may not yield desired returns, and the company's management has broad discretion over capital allocation.
- Solana is a highly volatile asset, and future fluctuations could result in significant losses.
- Momentum pricing and extreme volatility in digital asset trading prices, including SOL, could adversely affect the value of shares.
- Concentration of SOL holdings among a few treasury companies could lead to rapid price declines if one or more liquidate positions.
- Solana holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during market instability.
- Competition from other companies staking Solana and from other digital assets (Bitcoin, Ether, other smart contract platforms) could negatively influence SOL price.
- Failure to develop and execute successful investment or trading strategies, or trade errors, could result in losses.
- Laws and regulations affecting the CBD industry are evolving, and changes could materially affect future operations, including potential classification of hemp products as Schedule I controlled substances.
- Unfavorable interpretations of laws governing hemp processing activities could subject the company to enforcement actions.
- Costs associated with compliance with various laws and regulations in the CBD industry could negatively impact financial results.
- Uncertainty caused by potential changes to legal regulations could impact the use and acceptance of CBD products.
- Failure to obtain necessary permits, licenses, and approvals under applicable laws and regulations could adversely impact business.
- Potential future international expansion could expose the company to additional regulatory risks and compliance costs.
Future Outlook
Management expects to continue focusing on product sales, including the development, production, and distribution of branded products, alongside its digital asset treasury strategy. General and administrative expenses are anticipated to return to normal levels as business restructuring is largely complete by May 1, 2025. The company aims to return to cash flow positive and reduce expenses. It believes it will have sufficient working capital for the next twelve months and to meet debt obligations.
Management Comments
- Management has augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.
- Management expects that these declines (in revenue) are temporary as the primary factor was the transition and consolidation of the business to facilities in Florida.
- Management expects that general and administrative expenses to return to normal levels as the restructuring of the operations is significantly complete as of May 1, 2025 and reserves have been already been increased to reserve assets that may not be fully realized.
- We plan to utilize intelligent capital markets issuance including the issuance of both equity and convertible debt where we may issue capital in an accretive fashion for the benefit of shareholders to purchase and hold more Solana.
- We will stake the majority of the Solana in our treasury to earn a staking yield and turn the treasury into a productive asset. Currently we are staking approximately 95% of our SOL treasury, and intend to maintain a similar or higher percentage going forward.
- We do not hedge our SOL and do not have plans to hedge our SOL in the future. We will purchase locked Solana at a discount to the current spot price, which will provide higher gains for our shareholders as the discount moves to par over time.
Industry Context
Upexi's strategic pivot into a Solana-focused digital asset treasury positions it within the rapidly evolving cryptocurrency and blockchain industry, specifically targeting the high-performance blockchain segment. This move contrasts with its traditional consumer products business, which operates in a highly competitive health and wellness market, including the regulated hemp/CBD sector. The company aims to leverage the perceived 'earlier lifecycle' and 'underexposure' of Solana compared to Bitcoin, seeking higher yields through staking. This strategy aligns with a growing trend of public companies exploring digital asset treasuries, but also exposes Upexi to the significant regulatory uncertainties and market volatility inherent in the crypto space, which is still maturing and subject to intense scrutiny from global financial regulators.
Comparison to Industry Standards
- The company's shift to a Solana treasury strategy is a notable divergence from its historical consumer products focus, making direct comparisons to traditional industry benchmarks challenging.
- Upexi's staking of approximately 95% of its SOL treasury is a high allocation, aiming to maximize yield, which is a common practice among crypto asset holders seeking passive income.
- The company's use of multiple qualified custodians (BitGo, Coinbase) and cold storage for over 98% of its SOL treasury aligns with best practices for institutional digital asset security, similar to other large crypto holders or funds.
- The stated goal of purchasing locked Solana at a discount to spot price is a strategy employed by some sophisticated crypto investors to capture additional value as discounts narrow, but it also introduces specific liquidity risks.
- The company's consumer product brands (LuckyTail, PRAX, Cure Mushrooms, Moonwlkr, Gumi Labs) operate in highly competitive e-commerce and health/wellness markets, where controlling manufacturing to distribution is cited as a competitive strength, a common strategy for niche brand owners.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Strategy Officer | NA | Brian Rudick | 2025-05-22 | New appointment to bring expertise in traditional finance and crypto. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Committee Establishment | Audit, Compensation, and Nomination & Governance Committees established by the Board. | 2021-01-27 | Enhances corporate oversight and adherence to public company governance standards. |
| Audit Committee Financial Expert | Mr. Lawrence Dugan determined to be an audit committee financial expert. | 2021-01-27 | Strengthens financial oversight and compliance expertise on the Audit Committee. |
| Code of Business Conduct and Ethics | Adopted a Code of Business Conduct and Ethics applicable to all directors, officers, and employees. | 2021-05-21 | Establishes ethical guidelines and promotes integrity across the organization. |
| Equity Incentive Plan Amendment | 2019 Equity Incentive Plan amended to increase shares available for issuance to 10,000,000. | 2025-06-01 | Provides more flexibility for equity-based compensation to attract and retain talent, but also increases potential for future dilution. |
Legal Proceedings
- A complaint was filed by the company in the United States District Court for the District of Nevada regarding potential dilution from fractional shares rounding up after the reverse stock split, aiming to eliminate said risk.
Related Party Transactions
- The company leases its Odessa, Florida manufacturing facility from MFA 2510 Merchant LLC, which is owned by CEO Allan Marshall, for $20,060 per month on a triple net basis.
- CEO Allan Marshall advanced the company $100,000 in June 2024, which was repaid in July 2024.
- Subsequent to December 31, 2024, CEO Allan Marshall advanced the company $400,000, which was settled in March 2025 by his purchase of 125,000 shares of Series A preferred stock.
- Allan Marshall was one of the minority interest buyers in the sale of VitaMedica, Inc. in June 2024.
- The company has a promissory note with Allan Marshall (Marshall Loan) with an original principal of $1,500,000, amended in November 2023 to 12% cash interest, with $500,000 currently outstanding.
- GSR Growth Investments LP, a related party of the asset manager GSR Strategies LLC, holds shared voting power over 4,006,210 shares of common stock (approximately 7.45%).
Stakeholder Impact
- Shareholders face significant dilution risk from current and future equity issuances, including the resale of 48,026,410 shares by selling stockholders and potential future capital raises up to $500 million.
- Shareholders are exposed to high volatility and regulatory uncertainty associated with the company's new Solana digital asset treasury strategy.
- Employees may benefit from the 2019 Equity Incentive Plan, which was amended to increase available shares for grants, potentially improving retention and motivation.
- Customers of the consumer product brands may see continued product development and direct-to-consumer expansion, but also potential impacts from supply chain disruptions or changes in consumer perception of hemp-based products.
- Creditors are impacted by the company's working capital deficit and reliance on new capital raises and the volatile digital asset market to meet debt obligations.
- Regulatory bodies are actively scrutinizing digital asset activities, and any adverse rulings could significantly impact the company's Solana strategy and overall business.
Next Steps
- Continue to build the SOL treasury strategy through intelligent capital markets issuance, including equity and convertible debt.
- Maintain staking of a similar or higher percentage of the SOL treasury (currently ~95%) to earn staking yield.
- Onboard a third qualified custodian as part of risk management for digital asset holdings.
- Launch the new PRAX brand in October 2024 with several innovative products to follow.
- Focus on direct-to-consumer expansion as a primary growth driver for the brands portfolio.
- Continue talent acquisition to support growth across various industries.
- Reduce overall distribution costs through consolidation of products and facilities.
- Monitor and manage liquidity to ensure the company can satisfy current obligations, maintaining liquid SOL and cash reserves.
- Management expects general and administrative expenses to return to normal levels as business restructuring is significantly complete by May 1, 2025.
- The company will continue to work with the lessor to resolve disputed lease payments for the Cygnet lease.
Key Dates
| Date | Description |
|---|---|
| 2018-09-05 | Company incorporated. |
| 2018-11-01 | Company entered into a lease for equipment. |
| 2019-11-13 | Company entered into a lease for a Nevada facility. |
| 2020-07-01 | Company purchased Infusionz LLC. |
| 2021-01-01 | Gene Salkind and Thomas C. Williams joined as Directors. |
| 2021-01-27 | Board established Audit, Compensation, and Nomination & Governance Committees. |
| 2021-05-01 | Company entered into a lease for an additional Nevada facility. |
| 2021-06-01 | Upexi Inc. became a listed company on the Nasdaq stock exchange. |
| 2021-08-01 | Company purchased the assets of VitaMedica Corporation. |
| 2021-10-01 | Company purchased Interactive Offers, LLC. |
| 2021-10-08 | Cygnet entered into a lease for a Florida facility. |
| 2021-10-26 | Effective closing date of Infusionz sale to Bloomios, Inc. |
| 2022-04-01 | Company purchased 55% of Cygnet Online, LLC. |
| 2022-04-15 | Company entered into a non-negotiable convertible promissory note (Cygnet Note). |
| 2022-05-24 | Shareholders consented and Board approved amendment of 2019 Plan to increase maximum shares. |
| 2022-06-01 | Company executed a promissory note with Allan Marshall (Marshall Loan). |
| 2022-08-13 | Company acquired the pet product brand LuckyTail. |
| 2022-10-01 | Company purchased E-Core Technology, Inc. |
| 2022-10-19 | Company entered into a loan agreement with Professional Bank for a mortgage on its N. Clearwater, Florida office. |
| 2022-10-28 | Company accepted an offer to sell Infusionz, LLC and certain manufacturing business. |
| 2023-02-22 | Company executed two promissory notes with investors for $560,000 and $2,150,000. |
| 2023-03-15 | Company entered a lease for approximately 20,400 square feet of warehouse and office space in Tampa, Florida. |
| 2023-07-01 | Company started operations in the Tampa, Florida distribution center. |
| 2023-07-25 | Company entered a lease for approximately 5,700 square feet of office space in Tampa, Florida for its corporate headquarters. |
| 2023-08-31 | Company sold Interactive Offers to Amplifyir Inc. |
| 2023-09-01 | Company completed the acquisition of the remaining 45% interest of Cygnet. |
| 2023-11-15 | Company executed amendments to promissory notes with Mr. Marshall and another investor, extending terms and adjusting interest rates. |
| 2024-01-18 | Company issued 25,081 shares of common stock as repayment of $500,000 of long-term debt. |
| 2024-03-18 | Company issued 5,000 shares of common stock as an incentive-restricted stock grant. |
| 2024-04-01 | Company entered into a lease agreement with MFA 2510 Merchant LLC (owned by CEO Allan Marshall) for a manufacturing facility in Odessa, Florida. |
| 2024-06-01 | Effective day of VitaMedica sale to three investors. |
| 2024-06-13 | Company sold VitaMedica, Inc. to three investors. |
| 2024-06-30 | Effective date of E-Core sale to E-Core Holdings, LLC. |
| 2024-07-08 | Building sold for $4,300,000. |
| 2024-08-01 | Product manufacturing fully moved from Nevada facility to Odessa, Florida. |
| 2024-09-18 | Company filed a Certificate of Change for a 1-for-20 reverse stock split. |
| 2024-10-03 | Reverse stock split became effective. |
| 2024-10-17 | Company regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. |
| 2025-01-01 | Company announced strategy of establishing a digital currency holding company and adopted ASU 2023-08 for crypto assets. |
| 2025-03-07 | Company executed a convertible note with two investors for $350,000. |
| 2025-03-12 | Allan Marshall purchased 125,000 shares of Series A preferred stock, settling a $400,000 advance. |
| 2025-04-20 | Company closed on a $100 million private placement offering. |
| 2025-04-23 | Company entered into an Asset Management Agreement with GSR Strategies LLC. |
| 2025-04-24 | Company entered new employment agreements with Allan Marshall and Andrew Norstrud. Issued 214,228 shares of common stock for debt repayment. Issued restricted stock grants of 222,000 shares. |
| 2025-05-01 | Company entered into a Custodial Services Agreement with BitGo Trust Company, Inc. |
| 2025-05-05 | Company entered into an Institutional Client Agreement with Coinbase Inc. |
| 2025-05-22 | Brian Rudick joined Upexi, Inc. as Chief Strategy Officer. |
| 2025-05-23 | Company entered into a credit facility with BitGo Prime, LLC for up to $20,000,000. |
| 2025-06-01 | 2019 Equity Incentive Plan amended to increase shares available for issuance to 10,000,000. |
| 2025-07-11 | Company entered into securities purchase agreements for a $50 million private placement offering. |
| 2025-07-14 | Equity Offering closed, resulting in $50 million gross proceeds. |
| 2025-07-16 | Company entered into securities purchase agreements for a $151.2 million secured convertible note offering in exchange for Solana. |
| 2025-07-17 | Company issued restricted stock grants of 2,250,000 shares. |
| 2025-07-25 | Company entered into a Common Stock Purchase Agreement with A.G.P./Alliance Global Partners for up to $500,000,000. |
| 2025-08-25 | Company and Purchasers agreed to amend the July 11, 2025 Securities Purchase Agreement. |
| 2025-08-28 | Closing price of Common Stock on Nasdaq was $8.09 per share. |
| 2025-09-15 | Date of this preliminary prospectus filing. |
Recommendation
holdThe company is undergoing a high-risk, high-reward strategic pivot into the volatile cryptocurrency market, specifically Solana. While the significant capital raises and improved gross profit margins are positive, the substantial revenue decline in the traditional business, the worsening working capital deficit, and the inherent regulatory and market risks of digital assets create considerable uncertainty. The long-term success of the Solana treasury strategy is unproven, and the company's ability to navigate regulatory complexities and market fluctuations will be critical. A 'hold' recommendation is appropriate given the mixed financial signals and the speculative nature of the new core business, advising investors to monitor the execution of the Solana strategy and the stabilization of the consumer products segment before making further investment decisions.
Keywords
Solana, Cryptocurrency, Digital Assets, Staking, Consumer Products, SEC Filing, S-1/A, UPXI, Treasury Strategy, Blockchain, Hemp Products, CBD, Private Placement, Convertible Notes, Risk Management, Corporate Governance, Financial Performance, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.